A detailed history of Sherbrooke Park Advisers LLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 42,895 shares of MXCT stock, worth $159,569. This represents 0.03% of its overall portfolio holdings.

Number of Shares
42,895
Previous 32,378 32.48%
Holding current value
$159,569
Previous $152 Million 18.11%
% of portfolio
0.03%
Previous 0.07%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.94 - $5.38 $41,436 - $56,581
10,517 Added 32.48%
42,895 $180 Million
Q4 2023

Feb 14, 2024

BUY
$2.6 - $5.24 $84,182 - $169,660
32,378 New
32,378 $152 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $378M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.